<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121175">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02114671</url>
  </required_header>
  <id_info>
    <org_study_id>1241.42</org_study_id>
    <secondary_id>2013-000767-88</secondary_id>
    <nct_id>NCT02114671</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Phototoxic Potential of Faldaprevir</brief_title>
  <official_title>A Randomised, Assessor-blind, Placebo and Active Controlled, Parallel Group Study to Assess the Phototoxic Potential of Faldaprevir (Administered Orally, Once Daily) for 6 Days in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      To investigate the potential of Faldaprevir to induce skin phototoxicity, immediate or
      delayed type, to UV light and visible light in healthy male and female subjects.  To
      investigate the degree, wavelength dependency, severity, pigmentation and morphology of the
      phototoxic effects.  The persistence of the phototoxic susceptibility will be explored
      following cessation of study medication.  Within a sunscreen sub-study, the efficacy of
      commercially available high factor sunscreen will also be assessed in terms of its potential
      to prevent any phototoxic skin responses seen.  The safety and tolerability of Faldaprevir
      will also be assessed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of subjects with drug related adverse events</measure>
    <time_frame>17 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in minimum erythema dose (MED) at each wavelength tested, before and during treatment. The change will be quantified by the phototoxic index at 24 hrs (delayed erythema) derived by dividing the baseline MED by that during treatment</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with drug related adverse events</measure>
    <time_frame>17 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of phototoxic effects by phototoxic index</measure>
    <time_frame>7 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Faldaprevir QD high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsules, oral administration with 240 ml water, fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Faldaprevir QD low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tablets/capsules, oral administration with 240 ml water, fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>capsules, oral administration with 240 ml water, fed conditions</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ciprofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>tablets, oral administration with 240 ml water, fed conditions</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir high dose</intervention_name>
    <description>capsules, oral</description>
    <arm_group_label>Faldaprevir QD high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>capsule, oral</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>tablets, oral</description>
    <arm_group_label>Ciprofloxacin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Faldaprevir low dose</intervention_name>
    <description>capsules, oral</description>
    <arm_group_label>Faldaprevir QD low dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Health male and female subjects with no clinically significant abnormality (according
             to the Investigator's assessment) identified from a complete medical history,
             physical examination, whole body skin assessment, 12-lead ECG, vital signs and
             clinical laboratory tests.  In particular, there should be no evidence of abnormal
             photosensitivity

          -  Sun-reactive skin phototype I, II, or III

        Exclusion criteria:

        - Any relevant deviation from healthy conditions.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Boehringer Ingelheim Call Center</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>1241.42.44001 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>April 11, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
